v3.26.1
Segment Information - Summary of Segment's Financial Information (Details)
 12 Months Ended
Dec. 31, 2025
USD ($)
segment
Dec. 31, 2024
USD ($)
Segment Reporting [Abstract]    
Number of operating segments | segment 1  
Revenue:    
Total revenue $ 1,030,193 $ 9,784
Cost of revenues 295,799 0
Indirect costs:    
Selling, general and administrative 8,763,376 9,156,061
Total operating expenses 14,286,728 23,461,269
Loss from operations (13,552,334) (23,451,485)
Sale of royalty and milestone rights, net 0 20,379,376
Other income (expense), net 153,060 (981,490)
Net loss (13,399,274) (4,053,599)
License fee revenue and other revenue    
Revenue:    
Total revenue 1,030,193 9,784
Reportable Segment    
Revenue:    
Total revenue 1,030,193 9,784
Cost of revenues 295,799 0
Direct program costs:    
Contra-R&D expenses (13,919,881) (7,685,533)
Total research and development direct program costs 2,958,892 9,638,927
Indirect costs:    
Contra R&D expenses (2,409,284) (1,199,548)
Total research and development indirect costs 2,564,460 4,666,281
Selling, general and administrative 8,763,376 9,156,061
Total operating expenses 14,286,728 23,461,269
Loss from operations (13,552,334) (23,451,485)
Sale of royalty and milestone rights, net 0 20,379,376
Interest expense 822,709 857,364
Interest income (679,740) (539,743)
Other income (expense), net (296,029) 663,869
Net loss (13,399,274) (4,053,599)
Contra-R&D expenses 13,919,881 7,685,533
Reportable Segment | License fee revenue and other revenue    
Revenue:    
Total revenue 1,030,193 9,784
Reportable Segment | Ovaprene    
Direct program costs:    
Direct program costs: 5,016,187 8,518,495
Contra-R&D expenses (2,500,000) (200,000)
Indirect costs:    
Contra-R&D expenses 2,500,000 200,000
Reportable Segment | Sildenafil Cream, 3.6%    
Direct program costs:    
Direct program costs: 1,143,221 2,361,052
Reportable Segment | Other advanced clinical stage programs    
Direct program costs:    
Direct program costs: 2,805,127 1,421,888
Contra-R&D expenses (2,900,000) 0
Indirect costs:    
Contra-R&D expenses 2,900,000 0
Reportable Segment | Phase 1 and Phase 1-ready clinical stage programs    
Direct program costs:    
Direct program costs: 1,548,800 761,721
Contra-R&D expenses (400,000) (1,300,000)
Indirect costs:    
Contra-R&D expenses 400,000 1,300,000
Reportable Segment | Preclinical stage programs    
Direct program costs:    
Direct program costs: 6,365,438 4,233,762
Contra-R&D expenses (8,100,000) (6,200,000)
Indirect costs:    
Contra-R&D expenses 8,100,000 6,200,000
Reportable Segment | Other development programs    
Direct program costs:    
Direct program costs: 0 27,542
Reportable Segment | Personnel-related (including stock compensation)    
Indirect costs:    
Indirect costs: 4,691,957 5,611,057
Reportable Segment | Other indirect costs    
Indirect costs:    
Indirect costs: $ 281,787 $ 254,772